{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:42:06Z","timestamp":1791420126298,"version":"4.3.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Castleman disease (CD) is a rare non-malignant lymphoproliferation of undetermined origin. Two major disease phenotypes can be distinguished: unicentric CD (UCD) and multicentric CD (MCD). Diagnosis confirmation is based on histopathological findings in a lymph node. We attempted to survey all cases of paediatric CD identified to date in France to set up a national registry aiming to improve CD early recognition, treatment and follow-up, within the context of a new national reference center (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.castleman.fr\">http:\/\/www.castleman.fr<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In 2016, we e-mailed a questionnaire to members of the French paediatric immunohaematology society, the paediatric rheumatology society and the Reference Centre for Castleman Disease to retrospectively collect cases of paediatric CD (first symptoms before age 18\u2009years). Anatomopathological confirmation was mandatory.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 23 patients (12 girls) with a diagnosis of UCD (<jats:italic>n<\/jats:italic>\u2009=\u200917) and MCD (<jats:italic>n<\/jats:italic>\u2009=\u20096) between 1994 and 2018. The mean age at first symptoms was 11.47\u00a0\u00b1\u20094.23\u2009years for UCD and 8.3\u00a0\u00b1\u20093.4\u2009years for MCD. The mean diagnosis delay was 8.16\u00a0\u00b1\u200910.32\u2009months for UCD and 5.16\u00a0\u00b1\u20095.81\u2009years for MCD. In UCD, the initial symptoms were isolated lymph nodes (<jats:italic>n<\/jats:italic>\u2009=\u200910) or lymph node associated with other symptoms (<jats:italic>n<\/jats:italic>\u2009=\u20097); fever was present in 3 patients. Five patients with MCD presented fever. No patients had HIV or human herpesvirus 8 infection. Autoinflammatory gene mutations were investigated in five patients. One patient with MCD carried a K695R heterozygous mutation in <jats:italic>MEFV<\/jats:italic>, another patient with MCD and Duchenne myopathy carried two variants in <jats:italic>TNFRSF1A<\/jats:italic> and one patient with UCD and fever episodes carried two heterozygous mutations, in <jats:italic>IL10RA<\/jats:italic> and <jats:italic>IL36RN<\/jats:italic>, respectively. Treatment of UCD was mainly surgical resection, steroids, and radiotherapy. Treatment of MCD included tocilizumab, rituximab, anakinra, steroids, chemotherapy, and splenectomy. Overall survival after a mean of 6.1\u00a0\u00b1\u20096.4\u2009years of follow-up, was 100% for both forms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Paediatric CD still seems underdiagnosed, with a significant diagnosis delay, especially for MCD, but new international criteria will help in the future. Unlike adult CD, which is strongly associated with HIV and human herpesvirus 8 infection, paediatric CD could be favored by primary activation of innate immunity and may affect life expectancy less.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-1345-5","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T05:02:24Z","timestamp":1587099744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The French paediatric cohort of Castleman disease: a retrospective report of 23 patients"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2310-7930","authenticated-orcid":false,"given":"Charlotte","family":"Borocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ballot-Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oanez","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Aladjidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Delaleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vannina","family":"Giacobbi-Milet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Jannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jeziorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Maurier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Perel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Piguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Oksenhendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Kon\u00e9-Paut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Galeotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"1345_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/JBM.S60514","volume":"7","author":"K-L Chan","year":"2016","unstructured":"Chan K-L, Lade S, Prince HM, Harrison SJ. Update and new approaches in the treatment of Castleman disease. J Blood Med. 2016;7:145\u201358. https:\/\/doi.org\/10.2147\/JBM.S60514.","journal-title":"J Blood Med"},{"issue":"5","key":"1345_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27613","volume":"66","author":"J Sopfe","year":"2019","unstructured":"Sopfe J, Endres A, Campbell K, Hayes K, Trout AT, Liang X, et al. Castleman disease in pediatrics: insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. Pediatr Blood Cancer. 2019;66(5):e27613. https:\/\/doi.org\/10.1002\/pbc.27613.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"1345_CR3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","volume":"74","author":"K Yoshizaki","year":"1989","unstructured":"Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease. Blood. 1989;74(4):1360\u20137.","journal-title":"Blood"},{"issue":"10","key":"1345_CR4","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.arcped.2004.06.035","volume":"11","author":"C Piguet","year":"2004","unstructured":"Piguet C, Dubouill\u00e9 C, Petit B, Longis B, Paseaud E, De Lumley L. Castleman disease in a child. Arch Pediatr Organe Off Soc Francaise Pediatr. 2004;11(10):1252\u20134. https:\/\/doi.org\/10.1016\/j.arcped.2004.06.035.","journal-title":"Arch Pediatr Organe Off Soc Francaise Pediatr"},{"issue":"12","key":"1345_CR5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/MPH.0b013e31818ab31f","volume":"30","author":"C Galeotti","year":"2008","unstructured":"Galeotti C, Tran T-A, Franchi-Abella S, Fabre M, Pariente D, Kon\u00e9-Paut I. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report. J Pediatr Hematol Oncol. 2008;30(12):920\u20134. https:\/\/doi.org\/10.1097\/MPH.0b013e31818ab31f.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"1345_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/1535-7163.MCT-11-0972","volume":"11","author":"C Galeotti","year":"2012","unstructured":"Galeotti C, Boucheron A, Guillaume S, Kon\u00e9-Paut I. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody. Mol Cancer Ther. 2012;11(8):1623\u20136. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0972.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1345_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/jmedgenet-2017-105216","volume":"55","author":"ME Van Gijn","year":"2018","unstructured":"Van Gijn ME, Ceccherini I, Shinar Y, Carbo EC, Slofstra M, Arostegui JI, et al. New workflow for classification of genetic variants\u2019 pathogenicity applied to hereditary recurrent fevers by the international study Group for Systemic Autoinflammatory Diseases (INSAID). J Med Genet. 2018;55(8):530\u20137. https:\/\/doi.org\/10.1136\/jmedgenet-2017-105216.","journal-title":"J Med Genet"},{"key":"1345_CR8","doi-asserted-by":"publisher","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 2017. https:\/\/doi.org\/10.1182\/blood-2016-10-746933.","DOI":"10.1182\/blood-2016-10-746933"},{"issue":"2","key":"1345_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bjh.15019","volume":"180","author":"E Oksenhendler","year":"2018","unstructured":"Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180(2):206\u201316. https:\/\/doi.org\/10.1111\/bjh.15019.","journal-title":"Br J Haematol"},{"issue":"1049","key":"1345_CR10","doi-asserted-by":"publisher","first-page":"20140670","DOI":"10.1259\/bjr.20140670","volume":"88","author":"AJ Hill","year":"2015","unstructured":"Hill AJ, Tirumani SH, Rosenthal MH, Shinagare AB, Carrasco RD, Munshi NC, et al. Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients. Br J Radiol. 2015;88(1049):20140670. https:\/\/doi.org\/10.1259\/bjr.20140670.","journal-title":"Br J Radiol"},{"issue":"4","key":"1345_CR11","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","volume":"3","author":"AY Liu","year":"2016","unstructured":"Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman\u2019s disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163\u201375. https:\/\/doi.org\/10.1016\/S2352-3026(16)00006-5.","journal-title":"Lancet Haematol"},{"key":"1345_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.clinimag.2018.03.010","volume":"50","author":"N Rassouli","year":"2018","unstructured":"Rassouli N, Obmann VC, Sandhaus LM, Herrmann KA. (18F)-FDG-PET\/MRI of unicentric retroperitoneal Castleman disease in a pediatric patient. Clin Imaging. 2018;50:175\u201380. https:\/\/doi.org\/10.1016\/j.clinimag.2018.03.010.","journal-title":"Clin Imaging"},{"issue":"1","key":"1345_CR13","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1542\/peds.2010-2739","volume":"129","author":"S Leroy","year":"2012","unstructured":"Leroy S, Moshous D, Cassar O, Reguerre Y, Byun M, Pedergnana V, et al. Multicentric Castleman disease in an HHV8-infected child born to consanguineous parents with systematic review. Pediatrics. 2012;129(1):e199\u2013203. https:\/\/doi.org\/10.1542\/peds.2010-2739.","journal-title":"Pediatrics"},{"key":"1345_CR14","doi-asserted-by":"publisher","unstructured":"Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, De Somer L, Dooley J, Tousseyn T, et al. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. Pediatrics. 2018;142(3). https:\/\/doi.org\/10.1542\/peds.2017-2266.","DOI":"10.1542\/peds.2017-2266"},{"key":"1345_CR15","doi-asserted-by":"publisher","unstructured":"Boutboul D, Fadlallah J, Chawki S, Fieschi C, Malphettes M, Dossier A, et al. Treatment and outcome of Unicentric Castleman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019. https:\/\/doi.org\/10.1111\/bjh.15921.","DOI":"10.1111\/bjh.15921"},{"key":"1345_CR16","doi-asserted-by":"publisher","unstructured":"Talat N, Belgaumkar AP, Schulte K-M. Surgery in Castleman\u2019s disease: a systematic review of 404 published cases. Ann Surg. 2012;255(4):677\u201384. https:\/\/doi.org\/10.1097\/SLA.0b013e318249dcdc.","DOI":"10.1097\/SLA.0b013e318249dcdc"},{"issue":"9","key":"1345_CR17","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","volume":"15","author":"F van Rhee","year":"2014","unstructured":"van Rhee F, Wong RS, Munshi N, Rossi J-F, Ke X-Y, Foss\u00e5 A, et al. Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(14)70319-5.","journal-title":"Lancet Oncol"},{"key":"1345_CR18","doi-asserted-by":"publisher","unstructured":"van Rhee F, Voorhees P, Dispenzieri A, Foss\u00e5 A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115\u201324. https:\/\/doi.org\/10.1182\/blood-2018-07-862334.","DOI":"10.1182\/blood-2018-07-862334"},{"key":"1345_CR19","doi-asserted-by":"publisher","unstructured":"Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627\u201332. https:\/\/doi.org\/10.1182\/blood-2004-12-4602.","DOI":"10.1182\/blood-2004-12-4602"},{"key":"1345_CR20","doi-asserted-by":"publisher","unstructured":"Turcotte LM, Correll CK, Reed RC, Moertel CL. Sustained remission of severe multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr Blood Cancer. 2014;61(4):737\u20139. https:\/\/doi.org\/10.1002\/pbc.24761.","DOI":"10.1002\/pbc.24761"},{"key":"1345_CR21","doi-asserted-by":"publisher","unstructured":"Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, et al. The clinical spectrum of Castleman\u2019s disease. Am J Hematol. 2012;87(11):997\u20131002. https:\/\/doi.org\/10.1002\/ajh.23291.","DOI":"10.1002\/ajh.23291"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1345-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-1345-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1345-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T23:25:46Z","timestamp":1618615546000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-1345-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-1345-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"assertion":[{"value":"5 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No institutional review board approval was required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}